Aug. 13 at 2:39 AM
$IXHL $TNFA @DougieFreshPicks Isomyosamine in Phase 2b development for a number of conditions marked by acute & chronic inflammation. 🎯Read the Bottom
$IXHL🎯
Phase 1 and 2 it has demonstrated ability to suppress production of Other cytokines T00.
Notably a Differentiator compared to **current TNF-α Blockers of
$ABT requiring injection or infusion with risk of infection.
In✨✨ ✨ essence, isomyosamine appears to offer a novel approach to addressing inflammatory diseases by Selectively targeting and modulating unlike
$ABT that is a Blocker vs a Differentiator
$TNFA . ✨ ✨✨ Target the immuno-metabolic system, with a particular focus on TNF-α with it's role in conditions like Sarcopenia and several other serious diseases.✨ ✨ According to PubMed Central, TNF-α is at the top of the Signaling Cascade of pro-inflammatory Cytokines, making it a Critical Target in the management of autoimmune diseases ,inflammation Cytokines Storm = often fatal Not Rare condition. ✨ ✨..... @Butterflies5 POST 🎯 :AdvisorShares Investments LLC just filed Form 13F-HR with the SEC 8-5 disclosing ownership of 343,954 shares of
$IXHL
Why would AdvisorShares Investments LLC own both
$RMD and
$IXHL ?
I can NOT understand why a firm with half a Billion dollars under management buying a penny stock of
$IXHL? You Thinking about collaboration leading to a Merger with
$RMD. Needs a merger to be in lead of New Oral treatment for OSA.
